First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
Jordana K Schmier1, David W Covert21Managing Scientist, Exponent Inc., Alexandria, VA, USA; 2Associate Director, Health Economics, Alcon Research Ltd., Ft. Worth, TX, USAObjective: To estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care populati...
Guardado en:
Autores principales: | Jordana K Schmier, David W Covert |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e16ff5a2a1004b01bfc547753054c3fe |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
First-year treatment costs among new initiators of topical prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2009) -
Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2010) -
Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
por: Schmier JK, et al.
Publicado: (2014) -
Characteristics of respondents with glaucoma and dry eye in a national panel survey
por: Jordana K Schmier, et al.
Publicado: (2009) -
Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
por: Michael B Horsley, et al.
Publicado: (2009)